Home » Stocks » ALBO

Albireo Pharma, Inc. (ALBO)

Stock Price: $34.55 USD -0.63 (-1.79%)
Updated November 23, 2:45 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 659.12M
Revenue (ttm) 12.02M
Net Income (ttm) -90.36M
Shares Out 19.08M
EPS (ttm) -6.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $34.55
Previous Close $35.18
Change ($) -0.63
Change (%) -1.79%
Day's Open 35.18
Day's Range 34.55 - 35.50
Day's Volume 95,819
52-Week Range 11.26 - 49.00

More Stats

Market Cap 659.12M
Enterprise Value 389.93M
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 19.08M
Float 18.03M
EPS (basic) -6.14
EPS (diluted) -6.28
FCF / Share -5.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 643,297
Short Ratio 3.75
Short % of Float 3.57%
Beta 1.63
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 54.82
PB Ratio 3.17
Revenue 12.02M
Operating Income -84.72M
Net Income -90.36M
Free Cash Flow -85.25M
Net Cash 269.18M
Net Cash / Share 14.11
Gross Margin 80.15%
Operating Margin -704.65%
Profit Margin -751.50%
FCF Margin -709.07%
ROA -21.94%
ROE -57.66%
ROIC -4,935.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$68.25*
(97.54% upside)
Low
65.0
Current: $34.55
High
79.0
Target: 68.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.6412.74-11.365.10-----
Revenue Growth-24.36%1273900%-99.99%122.87%------
Gross Profit9.6412.74-11.365.10-----
Operating Income-61.11-37.89-24.58-12.29-4.73-19.26-20.59-19.30-23.22-37.16
Net Income-62.72-46.11-24.41-16.35-6.77-14.13-19.34-20.75-10.59-38.29
Shares Outstanding12.4411.707.821.240.270.710.520.360.260.20
Earnings Per Share-5.04-3.94-3.12-13.19-25.49-19.80-37.20-57.31-40.80-190.22
Operating Cash Flow-52.92-26.80-27.57-8.78-4.75-18.72-18.56-16.70-18.25-34.38
Capital Expenditures-0.54-0.054.31---0.05-0.12-0.06-0.19-0.29
Free Cash Flow-53.46-26.85-23.26-8.79-4.75-18.77-18.67-16.76-18.44-34.67
Cash & Equivalents13216453.2329.935.1224.5939.7839.1138.7629.07
Total Debt---3.087.38-----
Net Cash / Debt13216453.2326.86-2.2624.5939.7839.1138.7629.07
Assets16518573.2249.666.9725.4341.1541.1341.5132.62
Liabilities71.9162.837.9712.7115.202.638.5910.124.438.56
Book Value93.1612365.2536.95-8.7422.8032.5631.0237.0824.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Albireo Pharma, Inc.
Country United States
Employees 55
CEO Ronald H. W. Cooper

Stock Information

Ticker Symbol ALBO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALBO

Description

Albireo Pharma, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.